New drug could help patients with painful muscle disease ditch steroids

NCT ID NCT03632187

Completed Disease control Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether abatacept, a drug that calms the immune system, can control polymyalgia rheumatica (a painful inflammatory condition) without the need for long-term steroids. Thirty-four adults with early disease received either abatacept or a placebo for 12 weeks. The goal was to see if more patients could achieve low disease activity without steroids. The study is complete, and results will show if abatacept is a safer alternative to standard steroid treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abatacept (a drug that calms the immune system)
What this could lead to: If it works, this could offer a way to control polymyalgia rheumatica with less reliance on steroids, reducing side effects.
What could go wrong: This is a small, early-phase trial with only 34 participants. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polymyalgia rheumatica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYMYALGIA RHEUMATICA

Contacts and locations

Locations

CH Le Mans

Le Mans, France
CH St-Malo

St-Malo, France
CH de Morlaix

Morlaix, France
CHRU de Brest

Brest, France, 29609, France
CHU Strasbourg

Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.